NovoCure

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Stuttgart,,Germany,-,08-24-2023:,Person,Holding,Cellphone,With,Website,Of

Equities

Mid Cap

News

Movers

AIFU

APLD

BPMC

CRWV

KYMR

NVCR

RIOT

RXRX

SEZL

ZLAB

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?

cancer

Biotech

Health Care

Trading Ideas

General

TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.

NovoCure&#39;s Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Earnings

Guidance

NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure Ltd

Press Releases

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Novocure to Report First Quarter 2025 Financial Results

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure Reports First Quarter 2025 Financial Results

Novocure Announces Upcoming Investor Events

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Artivion

Alphatec Holdings

AtriCure

Beta Bionics

Conmed

Enovis

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

Kestra Medical Technologies, Ltd. - Common Stock

Kestra Medical Techs

LeMaitre Vascular

Masimo

Envista Holdings Corporation Common Stock

Envista Holdings

Omnicell

Penumbra

Pulse Biosciences

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

Smith & Nephew

Teleflex

TransMedics Group

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Piper Sandler

Wedbush

JP Morgan

HC Wainwright & Co.

Evercore ISI Group

Comments

NovoCure

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell